Novel 17β-substituted conformationally constrained neurosteroids that modulate GABAA receptors

Charikleia Souli, Nicolaos Avlonitis, Theodora Calogeropoulou, Andrew Tsotinis, G. Maksay, Tímea Bíró, Aggeliki Politi, Thomas Mavromoustakos, Alexandras Makriyannis, Heribert Reis, Manthos Papadopoulos

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

The goal of this study was to develop a series of allopregnanolone analogues substituted by conformationally constrained 17β side chains to obtain additional information about the structure-activity relationship of Set-reduced steroids to modulate GABAA receptors. Specifically, we introduced alkynyl-substituted 17β side chains in which the triple bond is either directly attached to the 17β-position or to the 21-position of the steroid skeleton. Furthermore, we investigated the effects of C22 and C20 modification. The in vitro binding affinity for the GABAA receptor of the new analogues was measured by allosteric displacement of the specific binding of [3H]4′-ethynyl-4-n-propyl-bicycloorthobenzoate (EBOB) to GABAA receptors on synaptosomal membranes of rat cerebellum. An allosteric binding model that has been successfully applied to ionotropic glycine receptors was employed. The most active derivative is (20A)-17β-(1-hydroxy-2,3-butadienyl)-5α-androstane-3-ol (20), which possesses low nanomolar potency to modulate cerebellar GABAA receptors and is 71 times more active than the control compound allopregnanolone. Theoretical conformational analysis was employed in an attempt to correlate the in vitro results with the active conformations of the most potent of the new analogues.

Original languageEnglish
Pages (from-to)5203-5214
Number of pages12
JournalJournal of Medicinal Chemistry
Volume48
Issue number16
DOIs
Publication statusPublished - Aug 11 2005

Fingerprint

GABA-A Receptors
Neurotransmitter Agents
Pregnanolone
Steroids
Glycine Receptors
Structure-Activity Relationship
Skeleton
Cerebellum
Conformations
Rats
Derivatives
Membranes
In Vitro Techniques

ASJC Scopus subject areas

  • Organic Chemistry

Cite this

Souli, C., Avlonitis, N., Calogeropoulou, T., Tsotinis, A., Maksay, G., Bíró, T., ... Papadopoulos, M. (2005). Novel 17β-substituted conformationally constrained neurosteroids that modulate GABAA receptors. Journal of Medicinal Chemistry, 48(16), 5203-5214. https://doi.org/10.1021/jm050271q

Novel 17β-substituted conformationally constrained neurosteroids that modulate GABAA receptors. / Souli, Charikleia; Avlonitis, Nicolaos; Calogeropoulou, Theodora; Tsotinis, Andrew; Maksay, G.; Bíró, Tímea; Politi, Aggeliki; Mavromoustakos, Thomas; Makriyannis, Alexandras; Reis, Heribert; Papadopoulos, Manthos.

In: Journal of Medicinal Chemistry, Vol. 48, No. 16, 11.08.2005, p. 5203-5214.

Research output: Contribution to journalArticle

Souli, C, Avlonitis, N, Calogeropoulou, T, Tsotinis, A, Maksay, G, Bíró, T, Politi, A, Mavromoustakos, T, Makriyannis, A, Reis, H & Papadopoulos, M 2005, 'Novel 17β-substituted conformationally constrained neurosteroids that modulate GABAA receptors', Journal of Medicinal Chemistry, vol. 48, no. 16, pp. 5203-5214. https://doi.org/10.1021/jm050271q
Souli, Charikleia ; Avlonitis, Nicolaos ; Calogeropoulou, Theodora ; Tsotinis, Andrew ; Maksay, G. ; Bíró, Tímea ; Politi, Aggeliki ; Mavromoustakos, Thomas ; Makriyannis, Alexandras ; Reis, Heribert ; Papadopoulos, Manthos. / Novel 17β-substituted conformationally constrained neurosteroids that modulate GABAA receptors. In: Journal of Medicinal Chemistry. 2005 ; Vol. 48, No. 16. pp. 5203-5214.
@article{e22a19b5bd994526844a0091111a8cae,
title = "Novel 17β-substituted conformationally constrained neurosteroids that modulate GABAA receptors",
abstract = "The goal of this study was to develop a series of allopregnanolone analogues substituted by conformationally constrained 17β side chains to obtain additional information about the structure-activity relationship of Set-reduced steroids to modulate GABAA receptors. Specifically, we introduced alkynyl-substituted 17β side chains in which the triple bond is either directly attached to the 17β-position or to the 21-position of the steroid skeleton. Furthermore, we investigated the effects of C22 and C20 modification. The in vitro binding affinity for the GABAA receptor of the new analogues was measured by allosteric displacement of the specific binding of [3H]4′-ethynyl-4-n-propyl-bicycloorthobenzoate (EBOB) to GABAA receptors on synaptosomal membranes of rat cerebellum. An allosteric binding model that has been successfully applied to ionotropic glycine receptors was employed. The most active derivative is (20A)-17β-(1-hydroxy-2,3-butadienyl)-5α-androstane-3-ol (20), which possesses low nanomolar potency to modulate cerebellar GABAA receptors and is 71 times more active than the control compound allopregnanolone. Theoretical conformational analysis was employed in an attempt to correlate the in vitro results with the active conformations of the most potent of the new analogues.",
author = "Charikleia Souli and Nicolaos Avlonitis and Theodora Calogeropoulou and Andrew Tsotinis and G. Maksay and T{\'i}mea B{\'i}r{\'o} and Aggeliki Politi and Thomas Mavromoustakos and Alexandras Makriyannis and Heribert Reis and Manthos Papadopoulos",
year = "2005",
month = "8",
day = "11",
doi = "10.1021/jm050271q",
language = "English",
volume = "48",
pages = "5203--5214",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "16",

}

TY - JOUR

T1 - Novel 17β-substituted conformationally constrained neurosteroids that modulate GABAA receptors

AU - Souli, Charikleia

AU - Avlonitis, Nicolaos

AU - Calogeropoulou, Theodora

AU - Tsotinis, Andrew

AU - Maksay, G.

AU - Bíró, Tímea

AU - Politi, Aggeliki

AU - Mavromoustakos, Thomas

AU - Makriyannis, Alexandras

AU - Reis, Heribert

AU - Papadopoulos, Manthos

PY - 2005/8/11

Y1 - 2005/8/11

N2 - The goal of this study was to develop a series of allopregnanolone analogues substituted by conformationally constrained 17β side chains to obtain additional information about the structure-activity relationship of Set-reduced steroids to modulate GABAA receptors. Specifically, we introduced alkynyl-substituted 17β side chains in which the triple bond is either directly attached to the 17β-position or to the 21-position of the steroid skeleton. Furthermore, we investigated the effects of C22 and C20 modification. The in vitro binding affinity for the GABAA receptor of the new analogues was measured by allosteric displacement of the specific binding of [3H]4′-ethynyl-4-n-propyl-bicycloorthobenzoate (EBOB) to GABAA receptors on synaptosomal membranes of rat cerebellum. An allosteric binding model that has been successfully applied to ionotropic glycine receptors was employed. The most active derivative is (20A)-17β-(1-hydroxy-2,3-butadienyl)-5α-androstane-3-ol (20), which possesses low nanomolar potency to modulate cerebellar GABAA receptors and is 71 times more active than the control compound allopregnanolone. Theoretical conformational analysis was employed in an attempt to correlate the in vitro results with the active conformations of the most potent of the new analogues.

AB - The goal of this study was to develop a series of allopregnanolone analogues substituted by conformationally constrained 17β side chains to obtain additional information about the structure-activity relationship of Set-reduced steroids to modulate GABAA receptors. Specifically, we introduced alkynyl-substituted 17β side chains in which the triple bond is either directly attached to the 17β-position or to the 21-position of the steroid skeleton. Furthermore, we investigated the effects of C22 and C20 modification. The in vitro binding affinity for the GABAA receptor of the new analogues was measured by allosteric displacement of the specific binding of [3H]4′-ethynyl-4-n-propyl-bicycloorthobenzoate (EBOB) to GABAA receptors on synaptosomal membranes of rat cerebellum. An allosteric binding model that has been successfully applied to ionotropic glycine receptors was employed. The most active derivative is (20A)-17β-(1-hydroxy-2,3-butadienyl)-5α-androstane-3-ol (20), which possesses low nanomolar potency to modulate cerebellar GABAA receptors and is 71 times more active than the control compound allopregnanolone. Theoretical conformational analysis was employed in an attempt to correlate the in vitro results with the active conformations of the most potent of the new analogues.

UR - http://www.scopus.com/inward/record.url?scp=23444457965&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23444457965&partnerID=8YFLogxK

U2 - 10.1021/jm050271q

DO - 10.1021/jm050271q

M3 - Article

C2 - 16078839

AN - SCOPUS:23444457965

VL - 48

SP - 5203

EP - 5214

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 16

ER -